Novo Nordisk inks $2.1B oral obesity drug deal / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance

Pfizer gets obesity drug approval in China shortly after buying local rights

5 days / endpoints / Elizabeth Cairns

Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

5 days / medicalxpress

Roche partner Zealand posts Phase 2 data for amylin obesity drug

5 days / endpoints / Kyle LaHucik

Novo Nordisk details Irish expansion; EuroAPI’s challenges continue

6 days / endpoints / Anna Brown

What to know about how GLP-1 medications might fight addiction

6 days / medicalxpress

Twenty percent of eligible youth prescribed GLP-1 receptor agonists

6 days / medicalxpress

GLP-1 medications get at the heart of addiction, study finds

6 days / medicalxpress

Quitting GLP-1 drugs triggers rapid regain, but 25% of weight loss may last

6 days / medicalxpress

Eli Lilly launches its direct-to-employer platform for obesity drugs

6 days / fiercehealthcare

Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds

6 days / nytimes / Roni Caryn Rabin

AHA urges HHS to block Novo Nordisk’s 340B data demand

6 days / beckershospitalreview / Paige Twenter

FDA sends Novo Nordisk 2nd warning over GLP-1 ads

6 days / beckershospitalreview / Erica Cerutti

How gut bacteria and diet can reprogram fat to burn more energy

7 days / medicalxpress

No more weekly injections? How lettuce cells could deliver GLP-1 pills

7 days / medicalxpress

GLP-1 weight-loss drugs comparably effective across age, race and starting weight

7 days / medicalxpress

FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters

7 days / fiercehealthcare

FDA warns 30 telehealth firms over compounded GLP-1 claims

7 days / beckershospitalreview / Ella Jeffries

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

8 days / endpoints / Shelby Livingston

Novo Nordisk inks $2.1B oral obesity drug deal

9 days / beckershospitalreview / Ella Jeffries

Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds

13 days / medcitynews / Frank Vinluan

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

14 days / endpoints / Kyle LaHucik

Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 21 stories in 8 days



Related Stories



Related Tags


Obesity

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

GLP‑1 drugs associated with lower addiction risk in large study (4 days)

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial (13 days)

more #obesity


Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare


Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals


StackHealth Time Machine



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.